Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK

Aladul, Mohammed I.; Fitzpatrick, R; Chapman, Stephen

doi:10.1007/s40259-017-0252-3

Cited by 44 publications

(40 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A survey of the literature revealed that budget impact analyses have been performed to estimate cost savings associated with the entry of infliximab and etanercept biosimilars before and after their market entry at national and international levels [16][17][18][19][20][21][22][23][24][25]. The majority of these budget impact analyses were based on third-party payer perspective (public health systems, payers, patients, and healthcare professionals).…”

Section: Introductionmentioning

confidence: 99%

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Aladul

Fitzpatrick

Chapman

2019

Research in Social and Administrative Pharmacy

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

Aladul

Fitzpatrick

Chapman

2019

Research in Social and Administrative Pharmacy

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the 2017-2018 financial year, the UK National Health Service saved £324 million through switching to biosimilars or generics for ten medicines, with almost £100 million saved through uptake of infliximab biosimilars [154]. Similarly, an analysis of rheumatology specialties in the UK (2014-2017) found that £38.8 million was saved over 2 years following the introduction of infliximab and etanercept biosimilars, because of biosimilar uptake and RP price reductions [155]. In Scandinavian countries, biosimilar availability has heralded significant cost savings and expanded patient access to biologics, despite already high use [10,132].…”

Section: Pharmacoeconomists' Perspective: Cost Of and Access To Biolomentioning

confidence: 99%

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Kim

Alten

Avedano³

et al. 2020

Drugs

View full text Add to dashboard Cite

Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars-biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators-can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.

show abstract

“…The value proposition of off-patent biologicals can be approached from two different perspectives: If accessibility to original biologicals is not restricted, after patent expiry multisource biologicals should generate savings without compromising health outcomes (i.e. 'disinvestment' scenario) [31,32]. However, the policy objective is different in those lower-income European countries where patient access to original biologicals is restricted.…”

Section: Introductionmentioning

confidence: 99%

Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

Harsányi

Csanádi

Márky³

et al. 2019

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Objectives: Utilization of multisource biological (off-patent originator and its biosimilar) medicines can improve the efficiency of resource allocation by 1) generating savings while maintaining health outcomes or 2) increasing the number of patients treated with more affordable treatments. This study evaluates the efficiency of the Hungarian biosimilar drug policy on the case of biosimilar infliximab. Methods: We analyzed the utilization of biologicals in all reimbursed indications of infliximab including initial therapy of new patients and switching patterns retrospectively based on patient-level payer's data between September 2012 and December 2016. Results: Despite the economic rationale, patent expiry did not manifest in increased utilization of multisource infliximab in an access-restricted environment: 1) Patients previously treated with original biologicals were switched mainly to other original biologicals instead of more affordable biosimilar alternatives. 2) Although some treatment-naive patients started on more affordable multisource infliximab with price competition, the majority of new patients started on other original biologicals with monopolistic price. Conclusion: Policy tools and measures should be developed to facilitate first-line use of multisource biologicals for treatment-naive patients and promoting the use of more affordable multisource biologicals in case of switching. ARTICLE HISTORY

show abstract

Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK

Cited by 44 publications

References 45 publications

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases

Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

Contact Info

Product

Resources

About